Second Amendment to License Agreement
This Second Amendment to License Agreement is dated February 26, 2024 (“Second Amendment”) and is entered into between Apogee Therapeutics, Inc., (“Licensee”) and MIL 6T, LLC (“Licensor”).
WHEREAS, Licensor and Licensee are parties to a certain License Agreement dated November 22, 2023, as amended by that certain First Amendment to License Agreement dated December 4, 2023 (“License Agreement”);
WHEREAS, Licensee warrants and represents that, to the best of its knowledge, Licensor has fulfilled its obligations under the License Agreement and is not in default of any covenants or obligations contained in the License Agreement;
WHEREAS, Licensor and Licensee desire to amend the License Agreement in certain respects as set forth herein; and,
WHEREAS, all capitalized terms contained herein shall, unless otherwise defined in this Second Amendment, have the same meaning as set forth in the License Agreement.
NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree that the License Agreement is hereby amended as follows:
IN WITNESS WHEREOF, Licensor and Licensee have duly executed this Second Amendment as of the date first written above.
SMARTLABS Licensee
By: /s/ Brian Taylor___________________ By: /s/ Steve Raso____________________
Title: Executive VP of Biopharma Solutions Title: SVP, Analytical Dev & QC, Apogee Therapeutics
Date: 2/26/2024